Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study. - Themenbild,Symbolfoto:Corona Impfstoff. Pfizer und BioNTech geben erfolgreiche erste Zwischenanalyse ihres COVID-19-Impfstoffkandidaten in laufender Phase-3-Studie bekannt. Einwegspritze mit Impfstoff zur Injektion mit einer Kanuele. BIONTECH Biotechnologie Unternehmen. (Photo by ddp images/Sipa USA)(Sipa via AP Images)
UK’s apex drug regulatory body, Medicines and Healthcare Regulatory Agency (MHRA), on Wednesday, issued an advisory for people with a history of significant allergic reactions, recommending them not to get vaccinated by the Pfizer/BioNTech COVID-19 vaccine.
MHRA advisory comes a day after two NHS workers, with a history of serious allergies, experienced severe allergic reactions to the m-RNA-based Pfizer vaccine.
ALSO READ
Lahore Traffic Warden Imposes the Biggest Fine of the Year on a Truck Driver
While both NHS workers are recovering now, doctors have claimed that they had suffered an anaphylactoid reaction after getting administered with the vaccine. An anaphylactoid reaction normally involves a skin rash, breathlessness, and sometimes a drop in blood pressure.
CEO MHRA, Dr. June Raine, has said the agency’s decision is the only right step to take at this moment.
Terming the advisory as only a precautionary measure, MD NHS England, Professor Stephen Powis, said this is common with new vaccines.
ALSO READ
China to Import Beef And Build Slaughterhouses in Pakistan
The UK kicked off a mass vaccination campaign on Tuesday, with 90-year-old Margaret Keenan becoming the first person in the world to receive the Pfizer COVID-19 vaccine.
Last week, MHRA had approved the Pfizer/BioNTech vaccine for mass vaccination campaigns across the UK after declaring it safe and effective on the basis of findings of the vaccine’s clinical trials.